CVR number 38746901
Industry 75.0000 Veterinary activities

ApS Centrum Dyreklinik Espergærde

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  17.1% 13.3% 10.1% 8.6% 6.0%  
Credit score (0-100)  9 16 23 27 39  
Credit rating  BB BB BB BB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  1,611 2,126 2,616 4,019 4,519  
EBITDA  772 805 540 1,259 1,369  
EBIT  665 705 399 947 1,066  
Pre-tax profit (PTP)  618.6 681.4 371.4 904.6 1,038.3  
Net earnings  713.9 530.7 283.4 699.8 803.3  
Pre-tax profit without non-rec. items  619 681 371 905 1,038  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  275 176 1,408 1,115 813  
Shareholders equity total  -295 236 333 1,033 1,560  
Interest-bearing liabilities  590 420 400 0.0 0.0  
Balance sheet total (assets)  1,132 1,367 2,261 3,080 2,620  
Net Debt  257 -343 289 -1,465 -1,207  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,611 2,126 2,616 4,019 4,519  
Gross profit growth  105.7% 32.0% 23.0% 53.7% 12.4%  
Employees  0 2 2 2 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,132 1,367 2,261 3,080 2,620  
Balance sheet change%  58.5% 20.8% 65.4% 36.2% -14.9%  
Added value  771.8 805.2 539.6 1,087.5 1,369.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -213 -199 1,091 -605 -606  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 4.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  41.3% 33.1% 15.2% 23.6% 23.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  42.3% 50.5% 22.0% 35.5% 37.4%  
ROI %  68.7% 105.7% 51.5% 97.1% 77.0%  
ROE %  77.3% 77.6% 99.6% 102.4% 62.0%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  -20.7% 17.3% 14.7% 33.5% 59.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  33.3% -42.6% 53.6% -116.4% -88.2%  
Gearing %  -200.1% 178.0% 120.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  5.0% 4.6% 6.7% 22.0% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.5 1.0 0.2 0.8 1.5  
Current Ratio  0.7 1.3 0.4 1.0 1.8  
Cash and cash equivalent  333.1 762.8 110.7 1,465.1 1,207.2  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -264.3 239.2 -1,089.1 -65.2 774.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 403 270 544 684  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 403 270 629 684  
EBIT / employee  0 352 199 473 533  
Net earnings / employee  0 265 142 350 402